MAINTENANCE LENALIDOMIDE IN NEWLY DIAGNOSED TRANSPLANT ELIGIBLE AND NON-ELIGIBLE MYELOMA PATIENTS; PROFILING SECOND PRIMARY MALIGNANCIES IN 4358 PATIENTS TREATED IN THE MYELOMA XI TRIALRESEARCH IN CONTEXT

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI TrialResearch in context

Summary: Background: Early trials of long-term lenalidomide use reported an increased incidence of second primary malignancy (SPM), including acute myeloid leukaemia and myelodysplastic syndrome.Later, meta-analysis suggested the link to be secondary to lenalidomide in combination with melphalan.Methods: Myeloma XI is a large, phase III randomised

read more